to a friend
We invite you to visit PAREXEL at these upcoming industry events. Events are a great way to get to know our experts, discuss your outsourcing challenges, and learn how PAREXEL’s global reach, technology and expertise can help your organization..
• As measured by new commercial IND submissions to the FDA's Center for Drug Evaluation and Research (CDER), clinical trial starts for new oncology drugs grew by 13% in 2007.
• New clinical trial starts for oncology drugs continue to represent the plurality of all clinical research starts annually. In 2007, the 111 oncology drug clinical research starts represented 15% of all clinical trials regulated by CDER. That is down slightly from the 16.5% rate in 2006.
• In addition, a significant percentage of the 83 clinical research starts for CDER-regulated biological INDs were also likely to be for cancer-related biological products.
• Meanwhile, actively conducted oncology-related clinical trials continue to represent the plurality of all active FDA-regulated clinical trials today. As of year-end 2007, oncology trials comprised 15.9% of all FDA-regulated trials actively being conducted. The closest were neurology trials, which comprised 9.6% of the total.
Source: PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2008/2009